# Contineum Therapeutics

Type: Company (CTNM)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/contineum-therapeutics
Canonical HTML page: https://getbiobrief.com/entity/contineum-therapeutics

## Timeline

- **2026-08-23**: Wall Street Zen upgrades both stocks to Hold — Wall Street Zen upgraded CTNM and ENVB from Sell to Hold in Sunday research notes.
- **2026-08-14**: Enveric reports quarterly loss — Enveric Biosciences reported EPS of -$0.76 for the quarter.
- **2026-07-31**: RBC raises CTNM target to $23 — Royal Bank of Canada raised its Contineum target from $22.00 to $23.00 with an Outperform rating.
- **2026-07-30**: Contineum reports Q2 results — Contineum reported Q2 EPS of -$0.40, beating consensus by $0.05.
- **2026-07-17**: Weiss Ratings reiterates Sell ratings — Weiss Ratings restated a Sell (d-) on CTNM and a Sell (e+) on ENVB.
- **2026-05-14**: Morgan Stanley raises CTNM target — Morgan Stanley raised its price target on Contineum Therapeutics from $14.00 to $16.00 with an Equal Weight rating.

## Recent coverage (1 stories)

### Wall Street Zen Upgrades 2 Biotechs: CTNM at $17.19, ENVB at $1.43
2026-08-24 11:32:21 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A rare double upgrade by Wall Street Zen moved Contineum Therapeutics and Enveric Biosciences from Sell to Hold, offering a momentary reprieve for two money-losing clinical-stage biotechs. CTNM trades near its 52-week high at $17.19 with a $20.25 consensus target, while ENVB's psychedelic pipeline carries a $6.41M market cap against a former $17.64 high.
Full story: https://getbiobrief.com/story/wall-street-zen-upgrades-two-biotechs-ctnm-envb-hold-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.